Literature DB >> 14699440

Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors.

S A Brody1, S C Dulawa, F Conquet, M A Geyer.   

Abstract

The glutamate hypothesis of schizophrenia derived from evidence that phencyclidine, a noncompetitive N-methyl-D-aspartate (NMDA) antagonist, produces schizophrenia-like symptoms in healthy humans. Sensorimotor gating, measured by prepulse inhibition (PPI), is a fundamental form of information processing that is deficient in schizophrenia patients and rodents treated with NMDA antagonists. Hence, PPI is widely used to study the neurobiology of schizophrenia. As the use of PPI as a model of gating deficits in schizophrenia has become more widespread, it has become increasingly important to assess such deficits accurately. Here we identify a possible role of mGluR5 in PPI by using wild type (WT) and mGluR5 knockout (KO) mice of two different background strains, 129SvPasIco and C57BL/6. In both strains, PPI was disrupted dramatically in the mGluR5 KO mice throughout a range of interstimulus intervals and sensory modalities. The present findings further support the glutamate hypothesis of schizophrenia and identify a functional role for mGluR5 in sensorimotor gating.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14699440     DOI: 10.1038/sj.mp.4001404

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  55 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 2.  Targeting glutamate synapses in schizophrenia.

Authors:  Julie R Field; Adam G Walker; P Jeffrey Conn
Journal:  Trends Mol Med       Date:  2011-09-28       Impact factor: 11.951

Review 3.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

4.  Environmental Enrichment Ameliorates Behavioral Impairments Modeling Schizophrenia in Mice Lacking Metabotropic Glutamate Receptor 5.

Authors:  Emma L Burrows; Caitlin E McOmish; Laetitia S Buret; Maarten Van den Buuse; Anthony J Hannan
Journal:  Neuropsychopharmacology       Date:  2015-02-10       Impact factor: 7.853

5.  Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling.

Authors:  Hong Wang; Linda Westin; Yi Nong; Shari Birnbaum; Jacob Bendor; Hjalmar Brismar; Eric Nestler; Anita Aperia; Marc Flajolet; Paul Greengard
Journal:  Science       Date:  2009-12-11       Impact factor: 47.728

Review 6.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 7.  Metabotropic glutamate receptors: physiology, pharmacology, and disease.

Authors:  Colleen M Niswender; P Jeffrey Conn
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

Review 8.  Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.

Authors:  P Jeffrey Conn; Craig W Lindsley; Carrie K Jones
Journal:  Trends Pharmacol Sci       Date:  2008-12-06       Impact factor: 14.819

9.  Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening.

Authors:  Ralf Mueller; Alice L Rodriguez; Eric S Dawson; Mariusz Butkiewicz; Thuy T Nguyen; Stephen Oleszkiewicz; Annalen Bleckmann; C David Weaver; Craig W Lindsley; P Jeffrey Conn; Jens Meiler
Journal:  ACS Chem Neurosci       Date:  2010-01-28       Impact factor: 4.418

10.  mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning.

Authors:  Jennifer E Ayala; Yelin Chen; Jessica L Banko; Douglas J Sheffler; Richard Williams; Alexandra N Telk; Noreen L Watson; Zixiu Xiang; Yongqin Zhang; Paulianda J Jones; Craig W Lindsley; M Foster Olive; P Jeffrey Conn
Journal:  Neuropsychopharmacology       Date:  2009-03-18       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.